CTOs on the Move

Navidea

www.navidea.com

 
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea`s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea`s strategy is to deliver ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.navidea.com
  • 4995 Bradenton Avenue Suite 240
    Dublin, OH USA 43017
  • Phone: 614.793.7500

Executives

Name Title Contact Details

Similar Companies

Gastro Care Partners

Gastro Care Partners is the national partner for successful regional gastroenterology practices. We equip practices with the resources necessary to thrive.

Reliable Biopharmaceutical

cladribine, fluphenazine decanoate, pentamidine isethionate, fludarabine phosphate, phentolamine, chloramphenicol, api, us api manufacturer, us api supplier, best gmp manufacturer, most reliable source of api

Aeryon Labs Inc

Aeryon Labs Inc is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

XIL Consulting

PBM consulting, provider nnetwork strategies, rebate benchmarking, global drug sourcing, client pricing, market assessments, MAC management, rebate aggregation.